The chronic disease known as asthma, which is characterised by inflammation of the airways, affects between 10 and 12 percent of children around the world and a sizeable percentage of adults. It is the ailment that affects children the most frequently and is a big contributor to the burden of health problems all around the world. In order to alleviate the enormous physical and financial burden that asthma exacerbations impose, it is essential to diagnose the condition at an early stage and to manage it effectively.
The use of artificial intelligence (AI) in healthcare has been a topic of interest for the past few years as this could be utilised to manage or prevent several diseases. Research on the AI-assisted home stethoscope, StethoMe, reveals its potential for detecting and monitoring asthma, particularly in children. This device can identify pathological auscultatory phenomena. It also measures parameters like heart rate, respiratory rate, and the ratio of inspiration-to-expiration duration.
The study found that the parameters provided by the AI-aided stethoscope alone were highly efficient in identifying asthma exacerbation in children. This indicates that AI-aided stethoscopes can facilitate the detection of exacerbations with high effectiveness. Even in children younger than five years of age. This is a significant advancement as asthma management in children is challenging due to the limitations of conducting standard physiologic tests.
The use of AI-aided stethoscopes in asthma management aligns with the shift towards value-based healthcare. AI-aided stethoscopes are a useful tool that can optimise and improve patient-doctor collaboration using telemedicine solutions. They also have the potential to improve asthma-related health outcomes, increase access to care, and offer cost-effectiveness. The study indicates that home stethoscopes, aided by AI, could simplify asthma diagnosis. They could monitor a wider range of parameters and significantly ease the process of asthma monitoring.
🌍 *Could a twice-yearly shot revolutionize HIV prevention?*
Gilead Sciences has submitted key applications to the EMA for lenacapavir, a groundbreaking HIV-1 capsid inhibitor designed for use as pre-exposure prophylaxis (PrEP). With promising trial results indicating a significant reduction in HIV infections, this innovation could enhance adherence to prevention strategies globally. Discover more about this game-changing development!
#SyenzaNews #globalhealth #healthcareInnovation
🌍 Can collaboration redefine Africa’s health landscape?
A newly signed Memorandum of Understanding between Africa CDC and Global Health EDCTP3 promises to enhance health research, clinical trials, and pandemic preparedness on the continent. With a focus on training, local manufacturing, and equitable partnerships, this initiative aims to address pressing global health challenges while improving health outcomes across Africa.
Look into the details of this transformative partnership and its implications for the future of healthcare in the region!
#SyenzaNews #globalhealth #HealthcareInnovation
🚨 Are we doing enough to tackle the imminent breast cancer crisis in Africa?
A recent WHO report reveals alarming trends, predicting that 135,000 women could succumb to breast cancer by 2040 unless urgent actions are taken. The report highlights critical gaps in healthcare infrastructure and capacity, emphasizing the need for investment in screening programs and professional training to improve outcomes across the continent.
Review the full article to explore the necessary steps towards reinforcing breast cancer control measures in Africa.
#SyenzaNews #globalhealth #oncology #HealthTech
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
